The p53 tumor suppressor plays key roles not only in preventing tumorigenesis, but
also in combating cancer progression. Missense p53 mutants are commonly detected in
cancers and their gain-of-functions (GOF) promote cancer progression. Wild-type p53
(wt-p53) protein is encoded from the TP53 gene, and serves as a guardian of genome
integrity. p53 triggers transcription and expression of p53-responsive genes, including
p21, Bax and Puma, thereby promoting cancer cell death and accordant cancer regression
(Figure 1). GOF resulting from p53 mutant proteins that are encoded from TP53 missense
mutations promotes cancer progression and causes emergent resistance to cancer chemotherapies
[1] (Figure 1). Codons 175, 248, and 273 are referred to as mutation “hotspots”, and
missense mutations at these loci are prevalently and commonly detected in cancers
of ovaries, colon and lungs [1]. Restoration of wt-p53 protein expression and function
in conjunction with ablation of mutants thus holds great promise for devising efficacious
anticancer therapies [2, 3]. Ceramides (Cer), which are sphingolipids, can act as
cellular signals to induce cancer cells to apoptosis, proliferation-arrest or autophagy
[4]. Recently, small Cer-RUB nanomicelles were identified as an agent for restoring
p53 tumor suppression and overcoming drug resistance as well as cancer progression
in ovarian cancer cells and tumors that carry p53 missense G248Q mutation [5].
Figure 1
p53 mutant proteins contribute to oncogenic gain-of-function (GOF) that promotes cancer
progression and emergence of drug resistance.
Cer-RUB nanomicelles restore wild-type p53 in cancer cells, thus inducing cancer cell
death and contributing to resultant cancer regression.
Cer-RUB nanomicelles effectively delivered a C6-ceramide (C6-Cer; a synthetic Cer
comprised of six carbons in the fatty acyl chain attached to sphingosine) into cells
and into tissues when administered to mice. C6-Cer is more potent than physiological
long-carbon chain ones (C12–24-Cers) for killing cancer cells. Exogenously delivered
C6-Cer not only increases levels of endogenous Cers, but also displays greater potency
in inducing cell death. C6-Cer is more slowly glucosylated (by glucosylceramide synthase,
GCS), and may be converted more slowly to the corresponding sphingosine-1-phosphate
(S1P) by deacylation (ceramidases) followed by phosphorylation (sphingosine kinases)
[5–7]. By exploiting these two prominent diversion pathways, metastatic cancers can
suppress free Cer levels, and furthermore, mount resistance to anticancer drugs via
elevated glucosylceramide and S1P [4, 7]. We adopted the natural and digestible glycoside
rubusoside (RUB), rather than any of the synthetic polymers that are commonly exploited
for the purpose (e.g., polyethylene glycol [PEG], polyethylenimine [PEI], poly[lactic-coglycolic
acid] [PLGA], graphene oxide), to encapsulate C6-Cer and generate small uniform Cer-RUB
nanomicelles (~32 nm). The nanomicelles exhibited greatly increased water-solubility
vs. C6-Cer, unquestionably contributing to improved bioavailability to cells in culture
and to tissues of mice. We did not detect any significant nonspecific toxicity of
RUB in cell culture or animal studies, even at significantly higher concentrations
or amounts than with the RUB-encapsulated Cer at the highest doses used. Pharmacokinetic
studies further indicate Cer-RUB nanomicelles can effectively deliver C6-Cer into
tumors and other tissues for various prospective therapeutic purposes, when administered
intraperitoneally or orally [5, 8].
The Cer-RUB nanomicelles are much more effective than C6-Cer delivered alone in sensitizing
cancer cells or tumors carrying p53 missense mutations to therapeutic agents, and
display high potential to be developed as a selective treatment for p53-mutant cancers.
Previous studies indicated that either exogenous C6-Cer provided or endogenous Cer
generated by suppression of Cer glycosylation restored wt-p53 protein and p53-dependent
tumor suppression in ovarian cancer cells carrying deletion-mutations in region coding
exon-5 of the p53 DNA-binding domain (18-bp deleted in NCI/ADR-RES cells, 21-bp deleted
in OVCAR-8 cells) [3, 9]. OVCAR-3 cancer cells homozygously carry TP53 R248Q missense
mutation and are resistant to many anticancer drugs, including cisplatin [5]. Cer-RUB
comparably delivered C6-Cer into OVCAR-3 and A2780 ovarian cancer cells (wt-p53),
or xenograft tumors generated therefrom. Significantly, namomicellular Cer-RUB proved
much more efficacious, upon concomitant treatment with cisplatin, in killing OVCAR-3
cells and ovarian cancer stem cells (CD24+/CD133+), and in inhibiting growth of corresponding
xenograft tumors, than was the case with A2780 cells or tumors [5]. Upon further assessment,
the re-sensitizing effects of Cer-RUB nanomicelles correlated with restored protein
levels of wt-p53 (phosphorylated at Ser15, pp53) and of p53-responsive genes (p21,
Bax). Further, Cer-RUB nanomicelles also restored the levels of pp53 and p21 in transgenic
mice carrying the p53 R172H/+ missense mutation [5]. The evidence accrued so far demonstrates
that Cer-RUB nanomicelles can be applied to restore p53-based tumor suppression in
cancers carrying the deletion-mutation, and hotspot missense mutation.
Although intriguing, more and more evidence supports a truth that Cer-RUB nanomicelles
or Cers are involved in restoring p53-dependent tumor suppression activity in cancer
cells carrying p53 mutations, most likely via modulating pre-mRNA splicing in post-transcription
processes. Based on experimental evidence, mutant cancer cells can generate pre-mRNA
transcripts molecules, including wt and mutant [3, 10]. Prior studies showed that
C6-Cer activate protein phosphatase-1, whence dephosphorylated serine/arginine-rich
splicing-factor 1 (SRSF1) is translocated to the nucleus, in turn promoting pre-mRNA
splicing to preferentially produce wt-p53 mRNA and protein [3, 9]. Most likely, Cer
modulates posttranscriptional processes to restore wt-p53 expression in OVCAR-3 cells
carrying TP53 R248Q mutation, though the mechanisms still need to be further detailed.
N
6-methyladenosine (m6A) generated at mutant codon, or m6As formed close to mutant
codons, also can alter the affinity of splicing factors and then spliceosome binding
favoring mutant p53 pre-mRNA to produce missense mutant [10]. Regardless, the Cer-RUB
nanomicelles, which enable delivery of Cer, even by oral route, to efficaciously restore
p53-dependent tumor suppression in a case where p53 mutations are extant, and reverse
emergent chemotherapy resistance, while sparing normal tissues. Cer-RUB nanomicells
hold great promise for improving treatment outcomes of cancers, notably for refractory
and recurrent cases where prognoses are otherwise poor.